SLC2A1 and cancer: SLC2A1 expression was elevated by 20.6-fold in pT1 and higher BC and by 7.7-fold in RPC compared to the non-BC control groups and other cancers, indicating that the overexpression of SLC2A1 is relatively specific to urothelial cancers.